Optiver Holding
TRVI icon

Optiver Holding’s Trevi Therapeutics TRVI Stock Holding History

Optiver Holding’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92K Sell
210
-456
-68% -$6.63K ﹤0.01% 2076
2026
Q1 		$7.95K Buy
666
+288
+76% +$3.22K ﹤0.01% 1278
2025
Q4 		$4.73K Sell
378
-510
-57% -$5.89K ﹤0.01% 1407
2025
Q3 		$8.13K Buy
+888
New +$6.66K ﹤0.01% 1425

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Optiver Holding's TRVI Position: Q2 2026 in Review

Optiver Holding reduced its Trevi Therapeutics (TRVI) stake by 68% in Q2 2026, selling an estimated $6.63K and leaving 210 shares worth $3.92K. The position accounts for ﹤0.01% of the portfolio, ranked #2076.

Optiver Holding first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. The position peaked at $8.13K in Q3 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Optiver Holding held 210 shares of Trevi Therapeutics worth $3.92K as of Q2 2026.
  • Optiver Holding sold 456 Trevi Therapeutics shares in Q2 2026, an estimated $6.63K.
  • Trevi Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2076 holding.
  • Optiver Holding first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Trevi Therapeutics position peaked at $8.13K in Q3 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.